Loading stock data…
PEN
$325.33-1.15 (-0.35%)
Market ClosedLast close May 1
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Penumbra, Inc. in the Healthcare sector is trading at $325.33. The stock is currently 10% below its 52-week high of $362.41, remaining 10.2% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why PEN maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$325.33
Potential Downside
72.8%
Whystock Fair Value$88.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Hold
Mean target$365.79+12.4%
Range$326.00 – $374.00
Fundamentals
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the In...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
73.66
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.35%
Volume
Today's trading volume
372,629
Recent News
Boston Scientific AGM: $20B 2025 Sales, Governance Votes Pass, Special Meeting Proposals Fail
Boston Scientific (NYSE:BSX) used its 2026 Annual Meeting of Stockholders to highlight 2025 operating performance and review a slate of governance and compensation proposals, including competing measures related to shareholders’ ability to call special meetings. Management highlights 2025 results a
Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback
Although a seemingly inopportune acquisition appears to have cost Boston Scientific dearly, the current valuation of BSX stock may be too enticing to pass up.
3 Reasons Why Penumbra (PEN) Is a Great Growth Stock
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Boston Scientific Q1 Earnings Call Highlights
Boston Scientific (NYSE:BSX) reported first-quarter 2026 results that landed near the top end of management’s prior guidance, while executives reduced their outlook for the remainder of the year citing “unanticipated headwinds” and changing business patterns in several key franchises. First-quarter
EY on the current state of the medtech industry
OEMs continue to prioritise high-growth segments of the medtech industry such as pulsed-field ablation (PFA), while conflict in the Middle East is impacting IPO activity.